These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 24533985)
1. Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans. Nye JA; Votaw JR; Bremner JD; Davis MR; Voll RJ; Camp VM; Goodman MM Nucl Med Biol; 2014 Mar; 41(3):217-22. PubMed ID: 24533985 [TBL] [Abstract][Full Text] [Related]
2. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Goodman MM; Kilts CD; Keil R; Shi B; Martarello L; Xing D; Votaw J; Ely TD; Lambert P; Owens MJ; Camp VM; Malveaux E; Hoffman JM Nucl Med Biol; 2000 Jan; 27(1):1-12. PubMed ID: 10755640 [TBL] [Abstract][Full Text] [Related]
3. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and Biological Evaluation of [ Cao S; Tang J; Liu C; Fang Y; Ji L; Xu Y; Chen Z Mol Imaging Biol; 2021 Oct; 23(5):733-744. PubMed ID: 33851345 [TBL] [Abstract][Full Text] [Related]
5. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. Zoghbi SS; Shetty HU; Ichise M; Fujita M; Imaizumi M; Liow JS; Shah J; Musachio JL; Pike VW; Innis RB J Nucl Med; 2006 Mar; 47(3):520-7. PubMed ID: 16513622 [TBL] [Abstract][Full Text] [Related]
6. (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Masilamoni G; Votaw J; Howell L; Villalba RM; Goodman M; Voll RJ; Stehouwer J; Wichmann T; Smith Y Exp Neurol; 2010 Dec; 226(2):265-73. PubMed ID: 20832405 [TBL] [Abstract][Full Text] [Related]
7. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I. Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927 [TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models. Seki C; Ito H; Ichimiya T; Arakawa R; Ikoma Y; Shidahara M; Maeda J; Takano A; Takahashi H; Kimura Y; Suzuki K; Kanno I; Suhara T Ann Nucl Med; 2010 May; 24(4):249-60. PubMed ID: 20364374 [TBL] [Abstract][Full Text] [Related]
9. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients. Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923 [TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel halo and tosyloxy nortropane derivatives as efficient precursors for the one-step synthesis of the dopamine transporter PET ligand [(18)F]FECNT. Pijarowska-Kruszyna J; Jaron AW; Kachniarz A; Kasprzak K; Kowalska A; Malkowski B; Demphel S; Dollé F; Mikolajczak R J Labelled Comp Radiopharm; 2014 Mar; 57(3):148-57. PubMed ID: 24497079 [TBL] [Abstract][Full Text] [Related]
12. Availability of dopamine transporters in heroin-dependent subjects: A Xu S; Liu Y; Li Y; Deng Y; Yuan J; Lv R; Wang Y; Zhang G; Guo Z; Fu D; Zeng H; Han M; Liu X Psychiatry Res Neuroimaging; 2017 May; 263():121-126. PubMed ID: 28376406 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of semi-quantitative method for quantification of dopamine transporter in human PET study with ¹⁸F-FE-PE2I. Ikoma Y; Sasaki T; Kimura Y; Seki C; Okubo Y; Suhara T; Ito H Ann Nucl Med; 2015 Oct; 29(8):697-708. PubMed ID: 26134215 [TBL] [Abstract][Full Text] [Related]
14. Quantification and discriminative power of Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633 [TBL] [Abstract][Full Text] [Related]
15. Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates. Varrone A; Stepanov V; Nakao R; Tóth M; Gulyás B; Emond P; Deloye JB; Vercouillie J; Stabin MG; Jonsson C; Guilloteau D; Halldin C J Nucl Med; 2011 Aug; 52(8):1313-21. PubMed ID: 21764797 [TBL] [Abstract][Full Text] [Related]
16. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease. Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993 [TBL] [Abstract][Full Text] [Related]
17. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112 [TBL] [Abstract][Full Text] [Related]
18. Semi-automated preparation of the dopamine transporter ligand [(18)F]FECNT for human PET imaging studies. Voll RJ; McConathy J; Waldrep MS; Crowe RJ; Goodman MM Appl Radiat Isot; 2005 Sep; 63(3):353-61. PubMed ID: 15985372 [TBL] [Abstract][Full Text] [Related]
19. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain. Van Laere K; Ahmad RU; Hudyana H; Dubois K; Schmidt ME; Celen S; Bormans G; Koole M J Nucl Med; 2013 Aug; 54(8):1285-93. PubMed ID: 23843566 [TBL] [Abstract][Full Text] [Related]